 |
15 Diseases |  |
1 Trial |
|
1 Trial |  |
19 News |  |
| «12 |
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: ALVAC-HIV vCP1452 Alone and Combined With MN rgp120 (clinicaltrials.gov) - Feb 19, 2014
P2, N=160, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=94, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion, Combination therapy: Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B (clinicaltrials.gov) - Feb 19, 2014
P2, N=330, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452 (clinicaltrials.gov) - Feb 19, 2014
P1, N=80, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination (clinicaltrials.gov) - Feb 19, 2014
P2, N=100, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination (clinicaltrials.gov) - Feb 19, 2014
P3, N=472, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine (clinicaltrials.gov) - Feb 19, 2014
P1, N=60, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers (clinicaltrials.gov) - Feb 19, 2014
P1, N=84, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers (clinicaltrials.gov) - Feb 19, 2014
P2, N=420, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | HIV vaccine vCP1521 / Sanofi, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
New P2 trial: Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX (clinicaltrials.gov) - Aug 11, 2013
P2, N=360, Not yet recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
- HIV vaccine vCP1521 / Sanofi, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Enrollment closed: Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144 (clinicaltrials.gov) - Jul 9, 2013
P2, N=162, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm (clinicaltrials.gov) - Oct 25, 2012
P1, N=18, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- | HIV vaccine vCP1521 / Sanofi, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: HIV Vaccine Trial in Thai Adults (clinicaltrials.gov) - Sep 3, 2012
P3, N=16402, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: A Study to Test the Safety of Three Experimental HIV Vaccines (clinicaltrials.gov) - May 15, 2012
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers (clinicaltrials.gov) - May 15, 2012
P1/2, N=48, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Enrollment change: Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers (clinicaltrials.gov) - May 2, 2012
P1, N=60, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=50 --> 60
- ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC (clinicaltrials.gov) - May 2, 2012
P1/2, N=0, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=50 --> 60 Active, not recruiting --> Completed
- HIV vaccine vCP1521 / Sanofi, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial initiation date: Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144 (clinicaltrials.gov) - Mar 14, 2012
P2, N=162, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Mar 2012
- ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers (clinicaltrials.gov) - Nov 14, 2011
P1, N=60, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Oct 2011 --> Mar 2012 Active, not recruiting --> Completed
- | HIV vaccine vCP1521 / Sanofi, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
New P2 trial: Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144 (clinicaltrials.gov) - Sep 13, 2011
P2, N=162, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command